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Abstract   
Background.  Betaine is the trimethyl derivative of glycine and is normally present in 
human plasma due to dietary intake and endogenous synthesis in liver and kidney. 
Betaine is utilized in the kidney primarily as an osmoprotectant whereas in the liver its 
primary role is in metabolism as a methyl group donor.  In both organs a specific betaine 
transporter mediates cellular uptake of betaine from plasma.  The abundance of both 
betaine and the betaine transporter in liver greatly exceeds that of other organs. 
Scope of review.  The remarkable contributions of betaine to normal human and animal 
health are summarized together with a discussion of the mechanisms and potential 
beneficial effects of dietary betaine supplements on liver disease. 
Major conclusions.  A significant amount of data from animal models of liver disease 
indicates that administration of betaine can halt and even reverse progression of the 
disruption of liver function. Betaine is well-tolerated, inexpensive, effective over a wide 
range of doses, and is already used in livestock feeding practices.  
General significance. The accumulated data indicate that carefully controlled additional 
investigations in humans are merited. The focus should be on the long-term use of 
betaine in large patient populations with liver diseases characterized by development of 
fatty liver, especially non-alcoholic fatty liver disease and alcoholic liver disease. 
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1. Introduction. 
 Betaine is an important human nutrient and human blood plasma typically 
contains 20-70 mol/liter which is not protein-bound. It is present in almost all tissues 
but the highest concentrations are in liver, kidney, and testes [1]. Some foods, such as 
whole grains, spinach, shrimp and beets, are rich in betaine and dietary intake is an 
important source.  In the USA, the average dietary betaine intake is about 100-300 
mg/day and rarely exceeds 400-500 mg. In addition, there is endogenous synthesis of 
betaine from choline, an essential nutrient, in the liver and also in the kidney. Excellent 
comprehensive summaries of some important biological roles of betaine have appeared in 
recent years [2-5]. One purpose here is to highlight recently emerging data on the 
therapeutic use of betaine and the possible mechanisms by which it can attenuate liver 
injury, especially in rodent models. 
2. Chemistry.                                                                                                            
 Betaine is the common term, and the one used throughout this review, that refers 
to a methyl derivative of glycine. The term glycine betaine is used increasingly to 
distinguish it from other betaine derivatives such as proline betaine and alanine betaine. 
Betaine (CAS # 107-43-7) is known also as trimethylglycine or N,N,N-
trimethylammonioacetate (IUPAC name). The pharmaceutical form of anhydrous betaine 
is marketed as Cystadane®. It was first discovered as a natural byproduct when sugar 
beets (Beta vulgaris) were processed for extraction of sucrose, and eventually was found 
to have a widespread distribution in many microorganisms, marine invertebrates, plants 
and animals. Beet is still the main source of commercially available betaine, and some 
physical and chemical properties of betaine are listed in Table 1. Over the physiological 
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pH range it is a zwitterion with a positively charged tri-methylammonium group and a 
negatively charged carboxyl group (Fig 1) and thus requires no counterions for 
electroneutrality in the cytoplasm. Betaine is stable, non-toxic and highly soluble in 
water. Strong acids convert anhydrous betaine to various salts. For example, hydrochloric 
acid produces betaine hydrochloride: 
(CH3)3N+CH2CO2− + HCl → [(CH3)3N+CH2CO2H]Cl− 
The hydrochloride form (CAS # 590-46-5) is used primarily as a source of hydrochloric 
acid for people with hypochlorhydria (low stomach acid). In the alkaline environment of 
the small intestine betaine hydrochloride is converted to betaine. 
 When betaine is released into the environment by excretion or death, especially in 
hypersaline environments, a variety of aerobic and anaerobic microorganisms degrade 
betaine. The degradation products include trimethylamine (CH3)3N and methylamine 
CH3NH2 from a number of different pathways [6-7]. Synthesis of betaine and subsequent 
demethylation in liver plays a vital role in one-carbon metabolism (Fig. 2).                                                       
  Betaine’s unique actions as an osmolyte and chemical chaperone are due to its 
underlying chemistry.  Osmolytes are small organic compounds that are accumulated by 
cells during stressful external conditions [8]. Organic osmolytes are compatible solutes 
because their interactions with macromolecules are not detrimental and they can be up- 
and down-regulated without interfering with cellular functions. In contrast, inorganic ions 
such as Na+ and Cl- can destabilize proteins and nucleic acids when present at high 
concentrations [9]. Additional interest in this group of compounds is due to their ability 
as chaperones to modify the structure and stability of macromolecules such as proteins 
and DNA [10]. This effect of betaine and similar osmolytes involves universal water-
BBAGEN-15-673 R2 
5 
 
solute-macromolecule interactions. Whereas destabilizers like ions and urea bind to 
proteins and cause them to unfold, betaine has the opposite effect. It does not bind and is 
excluded from protein’s immediate hydration layer causing the protein to fold more 
compactly, a so-called ‘osmophobic’ effect [8]. In brief, betaine becomes distributed non-
uniformly due to exclusion from proteins and this produces a thermodynamic force that 
drives proteins into a smaller volume in order to reduce the amount of excluded water. 
This stabilizes the proteins’ native structure. By focusing the osmophobic force on the 
denatured state, the native state is left free to function relatively unfettered by the 
presence of osmolyte [11]. This is supported by recent studies on the mechanism of 
protein stabilization by betaine [10] that showed a link between the influence of betaine 
(and other osmolytes) on water structure and the ability to stabilize protein structure.  In 
aqueous solution betaine is easily and tightly hydrated by strong hydrogen bonding with 
water molecules that extends from the carboxylate to the methyl groups (Fig. 1). There is 
easy exchange of water molecules between the hydration sphere of betaine and the bulk 
water, and the statistical average number of water molecules remaining constantly around 
the betaine molecule is very low [12]. Both values suggest that one water molecule, when 
attracted by a betaine molecule, is very rapidly substituted by another water molecule 
meaning that betaine does not immobilize water molecules. Water localization increases 
as betaine concentration increases and up to 12 water molecules can reside within the 
hydration shell of each betaine molecule with strong intramolecular forces acting 
between them and providing complex stability. Thus betaine enhances the surrounding 
water structure that excludes it from the immediate hydration layer of peptide backbones. 
 2.1. An intriguing question.   
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If betaine is excluded from protein surfaces how does it bind to transport proteins or 
enzymes ? The principal problem for binding is the very bulky quaternary amine group 
which has a positive charge distributed over a large volume resulting in a much smaller 
surface potential compared with a metal cation.  It cannot compete with small water 
molecules (with larger surface potentials) for binding sites on the surface of the 
transporter or enzyme protein. Clues were obtained from studies of betaine binding to a 
highly specific and high affinity betaine transport system (ProU) of E.coli. The binding 
protein of the ProU transport system solves this problem by forming a cavity with evenly 
distributed negative surface potential that is just large enough to accommodate the 
quaternary amine group of betaine. The positive charge of the quaternary amine forms 
noncovalent cation- interactions with electron-rich  bonds of the aromatic rings of 
three tryptophan residues in the cavity, termed an aromatic box, of the transport protein 
[13]. Such a specific requirement for binding a quaternary amine group likely avoids a 
considerable amount of non-specific binding to the betaine binding site of the transporter 
or enzyme protein.  The high affinity for betaine overcomes the osmophobic forces that 
restrict binding.                                                        
3. Roles of betaine in mammals.                                                                         
 Betaine has several vital roles in mammalian physiology and more are being 
uncovered (Fig. 3). Both the kidneys and liver, and perhaps other organs, contain cells 
that express specific transport systems to mediate uptake and accumulation of betaine 
from the blood supply [2-4]. The primary role in the kidney is osmoprotection in the cells 
in the inner medulla where the osmolarity is always high, but changing. Cellular 
adaptation to these conditions is a complex process [14, 15] that includes accumulation of 
BBAGEN-15-673 R2 
7 
 
betaine from the blood via the Na+- and Cl- -dependent betaine-GABA transporter 
(BGT1) transporter in the basal plasma membrane. Intracellular betaine, together with 
other organic molecules (osmolytes), balances the high extracellular osmolarity and 
maintains normal cell volume. As discussed earlier, betaine is an example of a non-
perturbing osmolyte because it can be accumulated to high concentrations (mmol/liter) 
without deleterious effects on the cells. Also, through its chaperone effect, intracellular 
proteins are protected from the denaturing effects of urea and NaCl which are present at 
high concentrations in the kidney medulla [16, 17].                                      
The betaine content of liver greatly exceeds that of other organs, except the 
kidney [1], and the abundance of the BGT1 transport protein is highest in liver compared 
to other organs [18]. Betaine in liver functions primarily as a methyl donor in one-carbon 
metabolism and there has been renewed interest in the therapeutic use of betaine for 
reducing liver injury. One-carbon metabolism is a metabolic network of interdependent 
biosynthetic pathways compartmentalized in the cytoplasm, mitochondria, and nucleus. 
For example, one-carbon metabolism in the nucleus plays a critical role in DNA 
replication and repair and in DNA methylation, a regulatory epigenetic process [19]. A 
simple abnormality in the methylation pathway, compounded with further assaults from 
environmental and infectious agents can lead to a wide range of conditions including, for 
example, cardiovascular disease, neurotransmitter imbalances, cancer, diabetes, abnormal 
immune function, and chronic inflammation. In the cytoplasm betaine is required for the 
remethylation of homocysteine to methionine [20, 21], a precursor to S-
adenosylmethionine (SAM), the universal methyl donor in the body. SAM donates its 
labile methyl group to more than 80 biological methylation reactions. Cells generate 
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SAM via the one-carbon pathway for transfer of a methyl group (Fig. 4). The methyl 
groups are provided by two donors, betaine and 5-methyltetrahydrofolate. 
Methyl groups are transferred from betaine to homocysteine in a reaction 
catalyzed by betaine-homocysteine methyltransferase (BHMT, Fig.4), the methionine 
cycle. It is notable that in both mouse and humans BHMT is most abundant in liver but 
also expressed in kidney [18, 22]. BHMT is a zinc metalloprotein, and catalysis follows 
an ordered bi-bi mechanism where homocysteine is the first substrate to bind to BHMT 
and dimethylglycine is the first product to leave [23]. Dimethylglycine is a strong non-
competitive inhibitor of BHMT, and betaine will not bind in the absence of homocysteine 
[24]. Homocysteine binding is facilitated by the presence of K+ ions which reduces the 
Michaelis constant (Km) for homocysteine but not betaine [25]. BHMT-2 has 80% 
identity to BHMT but cannot use betaine as the methyl donor, and shows almost no 
inhibition by dimethyl glycine [26, 27]. Methyl groups are transferred from 5-
methyltetrahydrofolate to homocysteine by methionine synthase (present in all tissues) in 
the folate cycle (Fig. 4), using methylcobalamin as a cofactor [2, 21]. Both enzymes 
contribute equally to remethylation of homocysteine in liver [2].                        
The major external source of methyl groups comes from the dietary supply of 
methionine, although dietary choline (metabolic precursor of betaine) and folate also are 
important [28]. Depletion of dietary folate alone is sufficient to diminish the methyl pool 
[29] and alcohol, a folate antagonist, also can deplete the methyl pool.  Excess 
consumption of alcohol impairs folate absorption by inhibiting expression of the folate 
transporter, thus decreasing the hepatic uptake and renal conservation of circulating 
folate. Alcohol consumption by rodents also produced significant decreases in liver 
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content of both SAM and betaine [30, 31].                                                                              
 Therapeutic applications of betaine have been used in both humans and animals.  
In humans betaine (6 g/day or more) has been effective in treating severe 
hyperhomocysteinemia, a risk factor for vascular complications and neurodegenerative 
diseases [3, 32] that arises due to the hereditary genetic disorder homocysteinuria. 
Betaine supplements in patients with mild hyperhomocysteinemia led to a rapid reduction 
of plasma homocysteine levels that was maintained over the long term [2]. Use of betaine 
in animal husbandry is well-established.  For many years it has been included in livestock 
feeds and is a safe method [33] to increase the lean muscle mass and decrease the fat of 
meat. This application consumes a major part of the world's betaine production. Its 
effectiveness is best documented in pigs, but similar responses are known in 
poultry and in lambs [3, 34]. How betaine affects body fat is not clear, but it has caught 
the attention of the bodybuilding and athletic performance industry. There are 
suggestions that betaine supplements can reduce fatigue and aid performance and 
recovery [2, 3], but research in human subjects has shown no effect on body weight or 
body composition [35]. 
More recently betaine was detected in mouse oviducts where it appears to 
increase after fertilization. It may act as an osmolyte in the developing embryo because 
preimplantation embryos accumulate betaine via the Na+-dependent imino acid 
transporter (SIT1). Further, the detection of endogenous betaine synthesis, high betaine 
concentrations, and BHMT activity in the mouse blastocyst suggests the importance of 
betaine in methylation reactions early in development. This is supported by observations 
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that inhibition of BHMT during embryogenesis resulted in developmental defects [36, 
37].  
4. Betaine in non-mammalian systems                                          
Betaine has been shown to have additional actions in non-mammalian systems, 
such as nematode worms, but the possible relevance to mammalian physiology has not 
been determined [38, 39].  Betaine also has found use as a cryoprotectant for frozen 
storage of microorganisms [40].                                                                                                       
Inclusion of betaine in feed used by salmon farms may help young fish raised in 
freshwater to maintain osmotic balance and grow faster when transferred abruptly to 
seawater [41, 42]. However, the data are few and not very convincing.                                                              
 As a zwitterion, and a small polar molecule prone to hydrogen bonding, betaine 
strongly interacts with water and other similar molecules, giving a ‘silkier’ feel to 
solutions, which explains its use in personal care products such as moisturizers and 
toothpaste [3].  
The polymerase chain reaction (PCR) process, and other DNA polymerase-based 
assays, such as DNA sequencing, can be enhanced by betaine. The amplification of 
contorted GC-rich regions and the product yield are improved in the presence of betaine. 
The mechanism is unknown but it may be due in part to facilitating strand separation and 
prevention of secondary structures in the DNA molecules. The overall effect is to 
equalize the contribution of GC-base pairs (strong) and AT- base pairs (weak) to the 
stability of the DNA duplex [43, 44]. The effect of betaine on the fidelity of the 
polymerase is another unknown, but it does not perturb the polymerase-DNA interaction 
or initial annealing of primer. In addition, the chemical chaperone action of betaine may 
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improve the resistance of DNA polymerase to denaturation. Experiments indicate betaine 
is best used at a final concentration of 0.8 -1.6 M although optimal conditions may need 
to be determined for specific amplification reactions [44, 45].                                              
5. Betaine transport in kidney and liver                                                                          
 Plasma betaine is filtered at the glomerulus of the kidney and is conserved 
efficiently by reabsorption along the nephron. The low fractional excretion of betaine 
indicates that filtered betaine is nearly completely reabsorbed from the tubular lumen in 
the proximal tubule and long loops of Henle [46]. The transport system that reabsorbs 
betaine in the proximal tubule resides in the luminal plasma membrane and may be the 
SIT1 transporter [47]. This is distinct from the BGT1 transporter in the medullary 
segments of the nephron that transports betaine from the blood supply and into the cells 
where it can accumulate, as discussed in section 3. Notably, the synthesis and expression 
of BGT1 is induced by osmotic stress and the mechanisms involved in these processes 
have been discussed already in several excellent reviews [14, 48-50]. The response to 
osmotic stress is relatively slow, at least in cultured cells, compared to acute 
downregulation by adenosine and upregulation by nitric oxide [51]. Some requirements 
for accurate targeting of BGT1 to the basolateral plasma membrane during osmotic stress 
have been reported by ourselves and others [52-56]. However while the structural and 
functional relationships of the bacterial betaine transporter BetP have been identified at 
the molecular level [57], similar analysis of the BGT1 protein remains superficial.                                           
 Recent data has shown that BGT1 is much more abundant in liver compared to 
kidney [18]. We confirmed the presence of BGT1 in hepatocyte plasma membranes and 
showed it is functional under iso-osmotic conditions. These initial studies also raised the 
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possibility that some betaine uptake in hepatocytes could utilize the ubiquitous transport 
systems for amino acids (SNAT) and carnitine (OCTN2). The multiple pathways for 
betaine accumulation likely reinforces the importance of betaine in normal liver function. 
However, the relative contributions of betaine uptake and betaine synthesis in 
maintaining liver betaine content is an unanswered question [31]. In developing rats the 
dietary betaine may be more important than synthesis [58].                                                                               
6. Liver diseases.                                                                                                               
 Many different pathogenetic agents and processes can affect the liver and cause 
diseases. Viruses like hepatitis A, B and C cause some of them. Others can be the result 
of drugs, toxins, excess alcohol consumption, and hereditary diseases. Those arising from 
acute damage to the functional cells of the liver (principally hepatocytes) without 
destroying regenerative capacity are generally reversible. Other consequences of liver 
disease are irreversible such as cirrhosis (scarring) where the liver becomes hard, 
shrunken and nodular and the amount of functioning tissue is decreased leading to 
impaired function. Despite having many different causes, a common feature of many 
liver diseases is fat accumulation in liver cells. Fatty liver (hepatic steatosis) occurs 
worldwide in the obese and in those with excessive alcohol intake. Here we focus on a 
significant body of evidence suggesting a novel therapeutic opportunity for the use of 
betaine on non-alcoholic fatty liver disease (NAFLD) caused by a combination of 
hereditary and environmental risk factors, and alcoholic liver disease (ALD) caused by 
alcohol abuse.                                                                                                                
 NAFLD is a common chronic liver disease worldwide with a prevalence that 
increases with increasing body weight. It is the most common cause of liver disease in 
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children and adolescents [59]. NAFLD includes a spectrum of abnormalities ranging 
from triglyceride accumulation in hepatocytes (often symptom-free) to non-alcoholic 
steatohepatitis (NASH). The latter involves infiltration of inflammatory cells and necrosis 
due to fat accumulation and can progress to cirrhosis of healthy tissue and liver failure. It 
is an increasing cause of liver transplantation. The mechanisms involved in NAFLD are 
not completely understood but one hypothesis for hepatocyte injury is the “two-hit” 
proposal [60]. The first hit is insulin resistance which leads to hepatic fat accumulation, 
characterized by macro- and micro-vesicular lipid droplets. The second hit involves 
mitochondrial dysfunction, lipid peroxidation and proinflammatory cytokines, leading to 
more serious damage and hepatocyte injury [61, 62]. NASH is of particular concern 
because it has significant potential for development of cirrhosis and its complications. 
Management is often directed at aggressive reduction of the risk factors, namely obesity 
and insulin resistance [63]. Insulin resistance, reflected as hyperinsulinemia, is positively 
correlated with elevated plasma homocysteine in NASH patients [64, 65]. In addition, 
there is decreased mitochondrial function and altered structure in NASH [66, 67].                                            
 ALD occurs after years of heavy alcohol consumption and is associated with fatty 
liver and progression to alcoholic hepatitis, cirrhosis and liver cancer. It is one of the top 
ten causes of death in developed countries. Symptoms vary with the severity of the injury 
and, surprisingly, not all heavy drinkers will develop clinically important ALD [68]. 
Alcohol consumption also may aggravate liver injury caused by non-alcoholic liver 
diseases such as chronic hepatitis C. Mild alcoholic hepatitis can be reversed by 
abstinence. Cirrhosis cannot be reversed but abstinence may prevent further injury. 
Cirrhosis is a major risk factor for development of hepatocellular carcinoma and it has 
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been estimated that 1% of the population worldwide has detectable cirrhosis. The only 
curative option for excessive cirrhosis is a liver transplant but some pharmacological 
strategies for halting the progression of cirrhosis are being studied [69, 70].                                                     
7. Use of betaine in liver injury due to NAFLD and ALD.                                        
 The use and effectiveness of betaine as a methyl donor supplement in both non-
alcoholic and alcoholic liver injury has been investigated. Exogenous betaine is 
inexpensive, well-tolerated, and has been used to decrease fat content of livestock 
carcasses and for treatment of hyperhomocysteinemia in humans [4, 34, 71]. It is notable 
that deletion of BHMT in mice, thus preventing removal of methyl groups from 
endogenous betaine, was associated with increases in fatty liver and hepatocellular 
carcinoma [22]. Fat accumulation in the liver may play a critical role not only in disease 
initiation, but also in the progression to NASH and cirrhosis. It has been proposed that 
prevention of fat accumulation in the liver may be an effective therapy for multiple stages 
of NAFLD [72]. Mice fed a moderately high fat diet for several weeks develop NAFLD 
[62]. However, providing dietary supplements of betaine at the same time increased SAM 
and prevented betaine deficiency, insulin resistance and steatosis in liver.  Furthermore, 
betaine administered after development of NAFLD reversed both insulin resistance and 
steatosis. These effects were attributed to normalization of downstream pathways 
involved in insulin signaling, gluconeogenesis and glycogen synthesis [73]. A similar 
study in mice reported that betaine restored adipose tissue function and sensitivity to 
insulin and suggested these actions may be due in part to relief of endoplasmic reticulum 
(ER) stress [74]. Attenuation of hepatic steatosis in mice by dietary betaine also was 
found to be associated with increased activation of hepatic AMP-activated protein kinase 
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(AMPK) [72], and both findings were confirmed in rats [75]. AMPK has been implicated 
in control of hepatic glucose and lipid homeostasis via multiple effects on genes and 
short-term regulation of specific enzymes. It has been suggested that alleviation of 
hepatic steatosis by betaine administration may be due to enhanced fatty acid oxidation 
and lipid export [75]. The mechanism may involve the down-regulation of genes 
involved in de novo synthesis and up-regulation of genes involved in fatty acid oxidation, 
based on a study of the action of betaine on genomic methylation. The dysregulation of 
expression of several relevant genes in NAFLD mice was corrected by betaine feeding 
[67].       
In summary, betaine action in NAFLD in rodents appears to involve multiple 
metabolic pathways. The critical step may be to regulate gene expression involved in 
fatty acid and lipid metabolism and thereby ameliorate development of hepatic steatosis. 
In turn, this may protect mitochondria from lipotoxicity due to failure of fatty acid 
oxidation [67] and relieve ER stress. Some of these effects may be due to indirect actions 
of betaine.  For example, betaine increases expression in liver of fibroblast growth factor 
21 which is a metabolic regulator [4].   
Although the underlying causes of NAFLD and ALD are clearly different, there 
are overlapping similarities in the histology, the disturbances in hepatic metabolic 
pathways, and some factors that appear to drive these changes. These are listed in Table 2 
and include insulin resistance, dysregulation of lipid metabolism, cytokines that mediate 
inflammation, and fibrosis and necrosis of hepatocytes. The role of the proinflammatory 
cytokine TNF- in mediating early stages of fatty liver and also the progression to liver 
injury has been determined from studies of both NASH and ALD [68].    
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Alcohol is thought to cause fatty liver by producing a decrease in fatty acid 
oxidation, and by stimulating lipogenesis. These effects may be due in part to inhibition 
of AMPK which controls fatty acid metabolism [76- 78]. Inhibition of AMPK by ethanol 
has been reported in both mice and in rat hepatoma cell lines [79]. The importance of this 
effect of ethanol was emphasized by the observation that treatment of ethanol-fed rats 
with a selective activator of AMPK attenuated the development of fatty liver [80]. 
Similarly, expression of a constitutively active form of AMPK in rat hepatoma cells also 
blocked some of the effects of ethanol [79].  Similar to its action in NAFLD, betaine has 
been reported to be protective of liver injury in animal models of ALD [81-83]. The 
enzyme methionine synthase, a vital enzyme for remethylation of homocysteine via the 
folate cycle, is inhibited by ethanol consumption [84, 85] and this may account for an 
increase in homocysteine in plasma. Under these conditions, dietary supplements of 
betaine likely provide an alternative pathway for remethylation of homocysteine via 
BHMT in the methionine cycle (Fig. 4). When betaine treatment was used to normalize 
homocysteine levels of alcohol-fed mice there was a decrease in fatty liver and 
inflammation and suppression of the ER stress response, suggesting 
hyperhomocysteinemia is a trigger for endoplasmic reticulum stress [84]. 
 Alterations in hepatic mitochondrial morphology and function are a hallmark of 
ALD. For example, alcohol-fed mice show an increased number of elongated 
mitochondria in liver and increased mitochondrial respiration [86]. These changes likely 
reflect an adaptive increase in the metabolism of alcohol. A separate proteomic study in 
livers of alcohol-fed rats detected decreases in several mitochondrial proteins involved in 
oxidative phosphorylation complexes. These decreases were prevented by co-feeding 
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betaine with the ethanol, suggesting that preservation of mitochondrial function may be 
an additional mechanism by which betaine protects the liver from alcoholic injury [87]. 
Direct application of betaine to a hepatocyte cell line was reported to increase 
mitochondrial respiraton and ATP content although concentrations in the millimolar 
range were required.  The mechanism was suggested to be indirect, possibly via 
intracellular signalling [88]. In other studies it has been suggested that betaine 
administration produces an increase in the rate of alcohol elimination through its indirect 
action to facilitate methylation of norepinephrine, converting it to epinephrine.  The 
proposed mechanism is that epinephrine increases the metabolic rate to increase the 
NAD+/NADH ratio, providing more NAD+ to catalyze destruction of ethanol by alcohol 
dehydrogenase [70].           
 Recent studies using an intestinal epithelial cell line showed that tight junctions 
were disrupted by ethanol and this effect was attenuated in the presence of betaine, 
suggesting that normal methylation activity helps to maintain tight junction integrity at 
least in an in vitro model [89]. It is possible to speculate, if alcohol and betaine have 
similar effects in vivo, that betaine offers additional protection by preventing pathogens 
in the gut from reaching the liver and contributing to hepatic inflammation and injury. 
 The progression of fatty liver to alcoholic hepatitis may be due to mechanisms 
triggered by metabolism of alcohol. These include disrupted methionine metabolism, 
induction of ER stress, increased susceptibility to TNF-, fibrosis and inflammation.  
Remarkably, as discussed above, betaine alleviates most of these problems, at least in 
experimental animals. It has even been suggested that the alcohol industry should add 
BBAGEN-15-673 R2 
18 
 
betaine to beer and wine so that drinkers could enjoy the effect of alcohol while reducing 
the risk of liver injury [70].      
8. Application to liver injury in humans      
 The results of betaine administration to humans with liver injury have proved to 
be disappointing so far and underline the challenges in translating therapeutic options 
from animal studies to the human population. For example, in a 12-month study of 55 
patients the administration of betaine did not improve hepatic steatosis or normalize liver 
enzymes in patients with NASH [63, 90]. This should not be the last word since only 35 
patients completed the study reducing the power to detect significant differences between 
the control and betaine-treated groups. In short, the study was underpowered and 
inconclusive which should not be interpreted as meaning there was no effect of betaine 
treatment on liver injury. It is also possible that additional factors may complicate studies 
of betaine action on liver injury in humans, and some will be considered here. 
 Before dealing with this issue it should be recognized that the liver processes 48% 
of dietary methionine to produce SAM [24]. As discussed earlier, BHMT and methionine 
synthase support the biosynthesis of methionine and SAM (Fig. 4). In most species, the 
majority of BHMT resides in the liver where its expression far exceeds that of other 
organs such as the kidney. In the liver it represents up to 2.0 % of the total soluble protein 
[24]. Deletion of BHMT in mice had dramatic effects such as an 8- fold increase in 
plasma homocysteine, a 21-fold increase in liver betaine content, and a 43% decrease in 
hepatic SAM content. The overall result was an estimated 75% reduction of methylation 
potential, and development of fatty liver within 5 weeks of age [22]. The importance of 
BHMT in hepatic betaine metabolism is further emphasized by its downregulation in 
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response to hyperosmotic stress, at least in rat hepatoma and renal cells [91, 92]. This 
may reflect the normal high rate of betaine consumption through the BHMT pathway 
because consumption must be reduced in order to conserve enough betaine to fulfill its 
osmolyte role in cell volume regulation. If abnormal hepatic gene expression is a major 
factor underlying development and progression of fatty liver disease [93], then BHMT 
could occupy a central role for alleviating the problem by supplying one-carbon units 
from betaine for methylation of specific genes.  If this is true then species differences in 
BHMT affinity for betaine might account in part for the apparent failure of betaine 
supplements to improve liver injury in humans. For example, a lower affinity of human 
BHMT for betaine might contribute to reduced effectiveness of betaine supplements for 
fatty liver injury. This might explain why very high doses of betaine (6 g/day or more) 
are required to reduce plasma homocysteine in humans. Values of Km and turnover 
numbers for BHMT taken from several publications are presented in Table 3. With 
betaine as substrate the Km values in rat and pig liver are somewhat variable but low, 
average 0.064 M, suggesting apparent high affinity for betaine. Corresponding Km for 
human BHMT vary widely with some values similar to rat while others exceed 2.0 mM, a 
more than 30-fold increase. In contrast the kcat for pig and human BHMT are comparable, 
based on the limited data. Some of the variability in Km for human BHMT has arisen 
even within the same research group and has been discussed but not explained [23]. 
Unfortunately direct comparisons of the kinetic constants of BHMT from animal and 
human liver determined under the same conditions in the same laboratory are not 
available.  Note that the values reported in Table 3 are exclusively for BHMT and do not 
include the BHMT-2 isoform which cannot utilize betaine (see section 3). 
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 The betaine concentration in tissue water was estimated to be 0.4 - 4.1 mM in rat 
liver [1, 31], assuming liver is 45% water by mass.  Under these conditions, rat BHMT 
would be fully active providing the homocysteine level was adequate, which is another 
issue. Based on one study [94] homocysteine was estimated to be 4-8 M in rat liver 
tissue water, below the range reported for the Km for homocysteine for BHMT (12-32 
) [95, 96] in rat liver. Little is known about betaine and homocyteine concentrations 
in human liver. Given these variables, it is difficult to compare the level of BHMT 
enzyme activity in vivo in animal and human liver, and the utilization of betaine 
supplements by this activity in vivo. In summary, although there are some indications that 
the human enzyme has a lower apparent affinity (higher Km) for betaine, the overall data 
remain equivocal (Table 3). The lack of improvement of human liver injury in response 
to betaine cannot be ascribed to different BHMT kinetics based on the evidence currently 
available. 
 Finally, in human studies it is not possible to verify directly that dietary betaine 
supplements lead to increased accumulation of betaine in the liver. Inadequate betaine 
uptake would lead to less than optimal responses to betaine treatment. Liver betaine 
uptake by BGT1, and other potential betaine transporters in liver such as SNAT and 
OCTN2 (see section 5), may be adversely affected by circulating metabolites which may 
be present in increased amounts due to liver disease. For example, a naturally occurring 
inhibitor of BGT1 is beta-alanine [50], a non-proteogenic amino acid which is produced 
endogenously in liver and also acquired through dietary intake. This and other, possibly 
unknown, factors also may impede betaine uptake via SNAT or OCTN2. Close attention 
to such issues may be necessary to optimize betaine treatment of human liver disease.  
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9. Conclusions          
 In summary, betaine is effective in alleviating most of the disturbances in both 
NAFLD and ALD, at least in animal models. This may be due in part to the similarities in 
liver dysfunction (Table 2) and the effectiveness of betaine to reverse changes in fatty 
acid and lipid metabolism that, in turn, relieve ER stress and restore mitochondrial 
function. Some caution is needed in interpreting data from different laboratories because 
the different animal models are not always consistent in terms of species (rats or mice) 
and treatment regimens used to develop the models. In one study, for example, rats 
appear to be more resistant to some aspects of liver injury by ethanol compared to mice 
[97. Regarding the disappointing effects of betaine in humans, a better understanding of 
BHMT kinetics in human liver is needed in order to improve the effectiveness of betaine 
treatment. Also, the action of betaine supplements may be influenced by existing clinical 
conditions and diet [3] suggesting that additional factors and specific population groups 
may need to be considered. The potential significant benefits of betaine, due to its 
multiple effects, its low cost, and the safety of oral doses in the range 3 – 30 g/day, 
strongly suggest additional human trials should utilize larger groups for longer duration 
and should be rigorously controlled.  
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CAS number 
 
107-43-7 
Molecular formula      
 
C5H11NO2 
Molecular wt  
 
117.1 
Color   
  
White hygroscopic crystals 
 
Taste  
 
Sweet 
Solubility 
 
(g/100g solvent) 
Water: 160.  Methanol: 57.  Ethanol 8.7. 
 
Aqueous solution is clear and colorless. 
 
pKa   
 
1.83 at 0 oC 
Melting point  
 
293 oC (decomposes) 
LD50  >10 g/kg body wt (rats) 
 
    
 
 
Table 1.  Physical and chemical properties of betaine.  
 
Date from reference [98]. 
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Liver disturbances common to both NAFLD 
and ALD 
Insulin resistance 
Dysregulation of genes involved in lipid metabolism 
Steatosis 
Mitochondrial dysfunction 
ER stress 
Decreased AMPK activity 
Proinflammatory cytokines (e.g.TNF-) released 
Hyperhomocysteinemia 
 
 
Table 2. Overlapping characteristics of liver dysfunction in non-alcoholic fatty liver 
disease (NAFLD) and alcoholic liver disease (ALD).  
Although the disease courses are quite divergent, the functional and histological 
disturbances are similar in NAFLD and ALD models, based on reports from many 
different laboratories. In rodent models NAFLD was induced by a high fat (or high 
sucrose) diet, and ALD was induced by chronic ethanol feeding. Almost all the 
disturbances, especially in ALD, were attenuated or reversed by dietary betaine 
supplements. See text, section 7, for details. 
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Table 3.  Comparison of Michaelis constant (Km) and turnover number (kcat ) for 
betaine homocysteine methyltransferase (BHMT) from animal and human liver.  
Rat or pig liver Human liver 
Km for betaine 
(mM) 
kcat for betaine      
(h-1) 
Km for betaine       
(mM) 
kcat for betaine       
(h-1)    
0.023 (pig) [96] 90 0.023 [26]  
0.048 (rat) [95] 
 
 0.075 [25] 107 
0.12  (rat) [99]  0.10 [100] 
0.12 [101] 
 
 
  1.7  [102]  
  2.2 [27] 88 
  2.47 [23]  
BBAGEN-15-673 R2 
35 
 
The kinetic constants determined with betaine as the substrate are taken from data 
published by several different laboratories. References in parentheses.  Data for BHMT-
2 are not included because this isoform cannot utilize betaine (see text, section 3). 
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Figure legends 
 
Fig. 1.  Betaine structure 
 
 
 
Fig. 2.  Pathway of betaine metabolism in liver. Choline from dietary intake is absorbed 
in the intestine and transported to the liver and kidneys. In the liver it is either 
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incorporated into phosphatidylcholine or converted into betaine . In the latter case, the 
first step (1) is oxidation in mitochondria via two reactions catalyzed by choline 
dehydrogenase (EC 1.1.99.1) followed by betaine aldehyde dehydrogenase (EC1.2.1.8).  
Betaine degradation continues in the cytosol (2) and requires betaine-homocysteine 
methyltransferase (BHMT, EC2.1.1.5). Step 3 is catalyzed by dimethylglycine 
dehydrogenase ((EC 1.5.99.2) in mitochondria.  Step 4 also in mitochondria requires 
sarcosine dehydrogenase (EC1.5.99.1). The final step (5) mediated by serine 
hydroxymethyltransferase (EC 2.1.2.1.) occurs in both mitochondria and cytosol. Overall, 
use of betaine for methylation of homocysteine by BHMT (step 2) recovers a methyl 
group to the methionine cycle and the remaining methyl groups enter the one-carbon 
pool. 
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Fig. 3.  Diverse roles of betaine. See text, sections 3-4, for details.  
 
 
 
Fig. 4.  Methionine cycle in liver. Conversion of homocysteine to methionine also occurs 
via the folate cycle (not shown in detail) which uses 5-methyltetrahydrofolate as a methyl 
donor in a reaction mediated by methionine synthase (EC 2.1.1.13) (2, 21).  See text, 
section 3, for further information.  BHMT, betaine-homocysteine methyltransferase.  
DMG, dimethylglycine. SAM, S-adenosylmethionine.  SAH, S-adenosylhomocysteine. 
